BETHESDA, Md., Nov. 13 /PRNewswire-FirstCall/ -- Spherix Incorporated
(Nasdaq: SPEX) reported a net loss for the three and nine months ended
September 30, 2008 of $1.7 million ($0.12 per share) and $4.8 million
($0.34 per share), respectively. Research and development and marketing
costs related to the commercialization of Naturlose as a treatment for Type
2 diabetes were approximately $3.2 million for the nine month period ended
September 30, 2008, compared to approximately $4.5 million for the same
period in 2007. Included in the prior year's income from continuing
operations was a $3.4 million tax benefit from the sale of the InfoSpherix
subsidiary in August 2007. Revenue from the Health Sciences Consulting
business continued its growth with a 19% increase between the second and
third quarter of 2008.
"Patient recruitment for our Phase 3 clinical trial in India is off to a very encouraging start with our Contract Research Organizations reporting that 120 patients have been screened already, with a much higher enrollment rate than experienced in the U.S. portion of the trial," said Spherix's CFO and Treasurer, Robert Clayton.
For the Three Months For the Nine Months
Ended Sept. 30, Ended Sept. 30,
2008 2007 2008 2007
continuing operations $308,000 $59,000 $714,000 $63,000
(Loss) income from
continuing operations $(1,735,000) $327,000 $(4,848,000) $(3,655,000)
operations $- $4,967,000 $- $4,913,000
Net (loss) income $(1,735,000) $
|SOURCE Spherix Incorporated|
Copyright©2008 PR Newswire.
All rights reserved